Stem definition | Drug id | CAS RN |
---|---|---|
antineoplastic, alkylating agents, (beta-chloroethyl)amine derivatives | 302 | 16506-27-7 |
None
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 1 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 6.26 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
Vd (Volume of distribution) | 0.22 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 4.49 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.05 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 0.41 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
March 20, 2008 | FDA | CEPHALON |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Progressive multifocal leukoencephalopathy | 343.72 | 19.38 | 128 | 13493 | 11218 | 46661223 |
Febrile neutropenia | 306.11 | 19.38 | 239 | 13382 | 94388 | 46578053 |
Neutropenia | 300.39 | 19.38 | 282 | 13339 | 142922 | 46529519 |
Pancytopenia | 253.88 | 19.38 | 205 | 13416 | 84853 | 46587588 |
Pyrexia | 230.67 | 19.38 | 384 | 13237 | 348418 | 46324023 |
Cytomegalovirus infection | 182.00 | 19.38 | 94 | 13527 | 18050 | 46654391 |
Diffuse large B-cell lymphoma | 165.27 | 19.38 | 63 | 13558 | 5875 | 46666566 |
Thrombocytopenia | 157.37 | 19.38 | 189 | 13432 | 126392 | 46546049 |
Neutrophil count decreased | 149.50 | 19.38 | 114 | 13507 | 43312 | 46629129 |
Chronic lymphocytic leukaemia | 138.73 | 19.38 | 46 | 13575 | 2854 | 46669587 |
Diffuse large B-cell lymphoma recurrent | 136.81 | 19.38 | 39 | 13582 | 1453 | 46670988 |
Plasma cell myeloma | 132.04 | 19.38 | 107 | 13514 | 44371 | 46628070 |
Lymphocyte count decreased | 127.00 | 19.38 | 84 | 13537 | 25505 | 46646936 |
B-cell lymphoma recurrent | 123.45 | 19.38 | 28 | 13593 | 404 | 46672037 |
Cytopenia | 103.96 | 19.38 | 49 | 13572 | 7719 | 46664722 |
Blood lactate dehydrogenase increased | 98.58 | 19.38 | 66 | 13555 | 20434 | 46652007 |
Tumour lysis syndrome | 94.85 | 19.38 | 45 | 13576 | 7191 | 46665250 |
Platelet count decreased | 84.91 | 19.38 | 124 | 13497 | 99900 | 46572541 |
Diffuse large B-cell lymphoma refractory | 78.59 | 19.38 | 23 | 13598 | 941 | 46671500 |
Product use in unapproved indication | 73.84 | 19.38 | 110 | 13511 | 90163 | 46582278 |
Prescribed underdose | 73.29 | 19.38 | 45 | 13576 | 12008 | 46660433 |
Lymphopenia | 72.95 | 19.38 | 49 | 13572 | 15244 | 46657197 |
Hypogammaglobulinaemia | 71.83 | 19.38 | 34 | 13587 | 5404 | 46667037 |
Autoimmune haemolytic anaemia | 66.80 | 19.38 | 30 | 13591 | 4228 | 46668213 |
Bone marrow failure | 64.92 | 19.38 | 60 | 13561 | 29609 | 46642832 |
Arthralgia | 64.30 | 19.38 | 14 | 13607 | 364589 | 46307852 |
Pneumocystis jirovecii pneumonia | 63.64 | 19.38 | 45 | 13576 | 15203 | 46657238 |
Disease progression | 63.15 | 19.38 | 103 | 13518 | 91197 | 46581244 |
Therapy partial responder | 61.00 | 19.38 | 29 | 13592 | 4653 | 46667788 |
Pneumonia | 59.70 | 19.38 | 242 | 13379 | 376078 | 46296363 |
Off label use | 56.89 | 19.38 | 240 | 13381 | 379601 | 46292840 |
White blood cell count decreased | 56.26 | 19.38 | 110 | 13511 | 112121 | 46560320 |
Erythropoiesis abnormal | 54.00 | 19.38 | 13 | 13608 | 246 | 46672195 |
Cytomegalovirus chorioretinitis | 53.01 | 19.38 | 19 | 13602 | 1488 | 46670953 |
CD4 lymphocytes decreased | 51.78 | 19.38 | 19 | 13602 | 1591 | 46670850 |
Cytokine release syndrome | 50.44 | 19.38 | 28 | 13593 | 6195 | 46666246 |
Extravasation | 50.20 | 19.38 | 20 | 13601 | 2095 | 46670346 |
Cytomegalovirus infection reactivation | 49.68 | 19.38 | 18 | 13603 | 1454 | 46670987 |
Fear of injection | 48.93 | 19.38 | 24 | 13597 | 4123 | 46668318 |
Headache | 48.70 | 19.38 | 41 | 13580 | 478311 | 46194130 |
Pain | 48.41 | 19.38 | 41 | 13580 | 476907 | 46195534 |
Gastrointestinal fungal infection | 48.40 | 19.38 | 12 | 13609 | 258 | 46672183 |
Varicella zoster virus infection | 48.22 | 19.38 | 20 | 13601 | 2323 | 46670118 |
Herpes zoster | 47.49 | 19.38 | 77 | 13544 | 67795 | 46604646 |
Non-small cell lung cancer | 45.68 | 19.38 | 21 | 13600 | 3123 | 46669318 |
Mantle cell lymphoma | 43.37 | 19.38 | 13 | 13608 | 578 | 46671863 |
Infusion related reaction | 43.37 | 19.38 | 93 | 13528 | 101115 | 46571326 |
B-cell lymphoma refractory | 43.17 | 19.38 | 9 | 13612 | 85 | 46672356 |
Leukopenia | 43.09 | 19.38 | 74 | 13547 | 68269 | 46604172 |
Venoocclusive liver disease | 42.52 | 19.38 | 22 | 13599 | 4229 | 46668212 |
Hepatitis B | 42.46 | 19.38 | 21 | 13600 | 3672 | 46668769 |
Myelosuppression | 42.39 | 19.38 | 27 | 13594 | 7676 | 46664765 |
Sinus polyp | 41.63 | 19.38 | 11 | 13610 | 307 | 46672134 |
Rash | 41.26 | 19.38 | 209 | 13412 | 356303 | 46316138 |
Chills | 40.87 | 19.38 | 88 | 13533 | 95944 | 46576497 |
Myelodysplastic syndrome | 40.77 | 19.38 | 35 | 13586 | 15676 | 46656765 |
Hypertensive cardiomyopathy | 39.77 | 19.38 | 10 | 13611 | 228 | 46672213 |
Drug hypersensitivity | 39.74 | 19.38 | 11 | 13610 | 243814 | 46428627 |
Drug interaction | 39.62 | 19.38 | 6 | 13615 | 203088 | 46469353 |
Lymphoma transformation | 38.46 | 19.38 | 9 | 13612 | 150 | 46672291 |
Plasma cell leukaemia | 38.08 | 19.38 | 14 | 13607 | 1179 | 46671262 |
Sepsis | 37.99 | 19.38 | 106 | 13515 | 135908 | 46536533 |
Infusion site irritation | 36.51 | 19.38 | 11 | 13610 | 498 | 46671943 |
Enterococcal sepsis | 36.49 | 19.38 | 14 | 13607 | 1326 | 46671115 |
Lymphoma | 36.47 | 19.38 | 27 | 13594 | 9786 | 46662655 |
Cerebral aspergillosis | 35.84 | 19.38 | 10 | 13611 | 344 | 46672097 |
Rash maculo-papular | 35.13 | 19.38 | 42 | 13579 | 27832 | 46644609 |
Toxic skin eruption | 35.03 | 19.38 | 29 | 13592 | 12358 | 46660083 |
Drug ineffective | 34.25 | 19.38 | 94 | 13527 | 677744 | 45994697 |
Hypercalcaemia | 33.84 | 19.38 | 36 | 13585 | 21010 | 46651431 |
JC virus infection | 33.57 | 19.38 | 14 | 13607 | 1648 | 46670793 |
Nasal abscess | 33.40 | 19.38 | 8 | 13613 | 148 | 46672293 |
B-cell lymphoma | 32.81 | 19.38 | 17 | 13604 | 3277 | 46669164 |
Platelet count abnormal | 32.58 | 19.38 | 16 | 13605 | 2756 | 46669685 |
Agranulocytosis | 32.28 | 19.38 | 36 | 13585 | 22149 | 46650292 |
Therapy responder | 31.29 | 19.38 | 9 | 13612 | 346 | 46672095 |
Chronic lymphocytic leukaemia recurrent | 31.19 | 19.38 | 8 | 13613 | 198 | 46672243 |
Abdominal discomfort | 30.56 | 19.38 | 4 | 13617 | 151161 | 46521280 |
Febrile bone marrow aplasia | 30.37 | 19.38 | 21 | 13600 | 6841 | 46665600 |
Haemolytic anaemia | 29.85 | 19.38 | 24 | 13597 | 9818 | 46662623 |
Cytomegalovirus colitis | 29.71 | 19.38 | 13 | 13608 | 1722 | 46670719 |
Atrial fibrillation | 29.17 | 19.38 | 81 | 13540 | 103509 | 46568932 |
Pneumonia fungal | 29.10 | 19.38 | 17 | 13604 | 4143 | 46668298 |
Dizziness | 29.03 | 19.38 | 34 | 13587 | 340380 | 46332061 |
Gait disturbance | 28.99 | 19.38 | 4 | 13617 | 145259 | 46527182 |
Mucosal erosion | 28.99 | 19.38 | 12 | 13609 | 1386 | 46671055 |
Condition aggravated | 28.77 | 19.38 | 18 | 13603 | 245034 | 46427407 |
Product dose omission issue | 28.59 | 19.38 | 7 | 13614 | 168513 | 46503928 |
Neutrophil count abnormal | 28.37 | 19.38 | 14 | 13607 | 2436 | 46670005 |
Peripheral swelling | 27.94 | 19.38 | 6 | 13615 | 158065 | 46514376 |
VIth nerve paresis | 26.96 | 19.38 | 6 | 13615 | 79 | 46672362 |
Listeria sepsis | 26.89 | 19.38 | 9 | 13612 | 574 | 46671867 |
Respiratory tract infection | 26.60 | 19.38 | 38 | 13583 | 29934 | 46642507 |
Anxiety | 26.46 | 19.38 | 10 | 13611 | 181947 | 46490494 |
Leukaemic lymphoma | 26.42 | 19.38 | 6 | 13615 | 87 | 46672354 |
General physical health deterioration | 26.40 | 19.38 | 84 | 13537 | 115685 | 46556756 |
Feeling abnormal | 26.03 | 19.38 | 3 | 13618 | 125057 | 46547384 |
Malignant neoplasm progression | 25.90 | 19.38 | 58 | 13563 | 64868 | 46607573 |
Insomnia | 25.82 | 19.38 | 8 | 13613 | 164916 | 46507525 |
Nonspecific reaction | 25.76 | 19.38 | 12 | 13609 | 1838 | 46670603 |
Haematotoxicity | 25.59 | 19.38 | 19 | 13602 | 6914 | 46665527 |
Enterococcal infection | 25.46 | 19.38 | 19 | 13602 | 6968 | 46665473 |
Infusion site extravasation | 25.44 | 19.38 | 17 | 13604 | 5239 | 46667202 |
Alopecia scarring | 25.31 | 19.38 | 6 | 13615 | 106 | 46672335 |
Infusion site pain | 25.17 | 19.38 | 22 | 13599 | 10085 | 46662356 |
Oral fungal infection | 25.02 | 19.38 | 13 | 13608 | 2521 | 46669920 |
Seborrhoeic dermatitis | 24.78 | 19.38 | 9 | 13612 | 732 | 46671709 |
Hypoglossal nerve paresis | 24.33 | 19.38 | 6 | 13615 | 126 | 46672315 |
Splenic marginal zone lymphoma recurrent | 24.17 | 19.38 | 4 | 13617 | 8 | 46672433 |
Urinary tract infection bacterial | 23.92 | 19.38 | 15 | 13606 | 4150 | 46668291 |
Infusion site phlebitis | 23.91 | 19.38 | 5 | 13616 | 48 | 46672393 |
Pneumonitis | 23.72 | 19.38 | 35 | 13586 | 28385 | 46644056 |
Fall | 22.00 | 19.38 | 39 | 13582 | 329058 | 46343383 |
Mucosal inflammation | 21.71 | 19.38 | 40 | 13581 | 38936 | 46633505 |
Nasopharyngitis | 21.51 | 19.38 | 9 | 13612 | 153989 | 46518452 |
Bronchiolitis obliterans syndrome | 21.11 | 19.38 | 5 | 13616 | 88 | 46672353 |
Schistocytosis | 20.93 | 19.38 | 4 | 13617 | 23 | 46672418 |
Varicella zoster oesophagitis | 20.25 | 19.38 | 4 | 13617 | 28 | 46672413 |
Second primary malignancy | 19.85 | 19.38 | 16 | 13605 | 6568 | 46665873 |
Hypertension | 19.70 | 19.38 | 17 | 13604 | 196339 | 46476102 |
Mantle cell lymphoma recurrent | 19.68 | 19.38 | 5 | 13616 | 119 | 46672322 |
Varicella zoster gastritis | 19.67 | 19.38 | 4 | 13617 | 33 | 46672408 |
Paraneoplastic pemphigus | 19.67 | 19.38 | 4 | 13617 | 33 | 46672408 |
Blood immunoglobulin G decreased | 19.64 | 19.38 | 10 | 13611 | 1858 | 46670583 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Febrile neutropenia | 453.62 | 16.66 | 463 | 20849 | 106230 | 29824936 |
Progressive multifocal leukoencephalopathy | 345.62 | 16.66 | 155 | 21157 | 8858 | 29922308 |
Pyrexia | 293.12 | 16.66 | 644 | 20668 | 293845 | 29637321 |
Neutropenia | 236.19 | 16.66 | 367 | 20945 | 128173 | 29802993 |
Tumour lysis syndrome | 185.29 | 16.66 | 115 | 21197 | 12770 | 29918396 |
Chronic lymphocytic leukaemia | 178.65 | 16.66 | 80 | 21232 | 4548 | 29926618 |
Lymphocyte count decreased | 164.29 | 16.66 | 124 | 21188 | 18931 | 29912235 |
Cytomegalovirus infection | 161.06 | 16.66 | 134 | 21178 | 23540 | 29907626 |
Myelodysplastic syndrome | 159.25 | 16.66 | 121 | 21191 | 18657 | 29912509 |
Neutrophil count decreased | 154.38 | 16.66 | 170 | 21142 | 42284 | 29888882 |
Diffuse large B-cell lymphoma | 141.42 | 16.66 | 81 | 21231 | 7760 | 29923406 |
Pancytopenia | 140.98 | 16.66 | 232 | 21080 | 84820 | 29846346 |
Product use in unapproved indication | 137.20 | 16.66 | 212 | 21100 | 73481 | 29857685 |
Cytomegalovirus chorioretinitis | 121.38 | 16.66 | 55 | 21257 | 3213 | 29927953 |
Thrombocytopenia | 117.93 | 16.66 | 284 | 21028 | 136760 | 29794406 |
End stage renal disease | 116.17 | 16.66 | 70 | 21242 | 7365 | 29923801 |
Prescribed underdose | 110.88 | 16.66 | 69 | 21243 | 7690 | 29923476 |
Disease progression | 105.19 | 16.66 | 197 | 21115 | 79677 | 29851489 |
B-cell lymphoma recurrent | 100.17 | 16.66 | 31 | 21281 | 612 | 29930554 |
Infusion related reaction | 99.32 | 16.66 | 133 | 21179 | 40431 | 29890735 |
Mantle cell lymphoma | 97.86 | 16.66 | 38 | 21274 | 1503 | 29929663 |
Neutropenic sepsis | 97.76 | 16.66 | 74 | 21238 | 11335 | 29919831 |
Cytopenia | 94.80 | 16.66 | 64 | 21248 | 8192 | 29922974 |
Autoimmune haemolytic anaemia | 92.67 | 16.66 | 49 | 21263 | 4010 | 29927156 |
B-cell lymphoma | 90.56 | 16.66 | 50 | 21262 | 4460 | 29926706 |
Off label use | 89.42 | 16.66 | 382 | 20930 | 248908 | 29682258 |
Extravasation | 88.21 | 16.66 | 37 | 21275 | 1791 | 29929375 |
Chills | 83.72 | 16.66 | 169 | 21143 | 72169 | 29858997 |
Second primary malignancy | 79.57 | 16.66 | 52 | 21260 | 6304 | 29924862 |
Hepatitis B reactivation | 72.17 | 16.66 | 37 | 21275 | 2840 | 29928326 |
Squamous cell carcinoma | 71.70 | 16.66 | 59 | 21253 | 10191 | 29920975 |
Myelosuppression | 70.61 | 16.66 | 51 | 21261 | 7271 | 29923895 |
Acute myeloid leukaemia | 68.67 | 16.66 | 74 | 21238 | 17932 | 29913234 |
Infusion site extravasation | 67.95 | 16.66 | 34 | 21278 | 2479 | 29928687 |
Diffuse large B-cell lymphoma recurrent | 67.69 | 16.66 | 32 | 21280 | 2060 | 29929106 |
Pneumonia | 66.37 | 16.66 | 435 | 20877 | 333871 | 29597295 |
Bone marrow failure | 65.86 | 16.66 | 93 | 21219 | 29692 | 29901474 |
Rash | 64.79 | 16.66 | 289 | 21023 | 191600 | 29739566 |
Pneumocystis jirovecii pneumonia | 64.66 | 16.66 | 70 | 21242 | 17050 | 29914116 |
Septic shock | 61.31 | 16.66 | 138 | 21174 | 63469 | 29867697 |
Basal cell carcinoma | 61.21 | 16.66 | 66 | 21246 | 16002 | 29915164 |
Therapy partial responder | 58.29 | 16.66 | 35 | 21277 | 3656 | 29927510 |
Drug interaction | 58.25 | 16.66 | 35 | 21277 | 199533 | 29731633 |
Cytokine release syndrome | 56.90 | 16.66 | 51 | 21261 | 9882 | 29921284 |
Chronic lymphocytic leukaemia recurrent | 55.33 | 16.66 | 18 | 21294 | 420 | 29930746 |
Malignant neoplasm progression | 54.86 | 16.66 | 143 | 21169 | 72144 | 29859022 |
Toxicity to various agents | 54.68 | 16.66 | 29 | 21283 | 177154 | 29754012 |
Infection | 52.78 | 16.66 | 148 | 21164 | 77926 | 29853240 |
Endocarditis noninfective | 52.00 | 16.66 | 13 | 21299 | 111 | 29931055 |
White blood cell count decreased | 50.85 | 16.66 | 153 | 21159 | 83794 | 29847372 |
Product dose omission issue | 50.12 | 16.66 | 4 | 21308 | 91627 | 29839539 |
Plasma cell myeloma | 48.20 | 16.66 | 113 | 21199 | 53349 | 29877817 |
Lymphoma transformation | 48.01 | 16.66 | 13 | 21299 | 156 | 29931010 |
Headache | 45.26 | 16.66 | 38 | 21274 | 182268 | 29748898 |
Arthralgia | 43.70 | 16.66 | 21 | 21291 | 135770 | 29795396 |
Atypical pneumonia | 43.46 | 16.66 | 26 | 21286 | 2698 | 29928468 |
Lymphopenia | 43.15 | 16.66 | 50 | 21262 | 13113 | 29918053 |
Infusion site phlebitis | 42.40 | 16.66 | 9 | 21303 | 33 | 29931133 |
Lymphadenopathy | 42.31 | 16.66 | 68 | 21244 | 24308 | 29906858 |
Rash maculo-papular | 41.54 | 16.66 | 69 | 21243 | 25349 | 29905817 |
Squamous cell carcinoma of skin | 41.19 | 16.66 | 41 | 21271 | 9054 | 29922112 |
Phlebitis | 40.34 | 16.66 | 28 | 21284 | 3747 | 29927419 |
Sepsis | 40.27 | 16.66 | 208 | 21104 | 146187 | 29784979 |
Mantle cell lymphoma recurrent | 40.06 | 16.66 | 14 | 21298 | 409 | 29930757 |
Neoplasm progression | 39.41 | 16.66 | 56 | 21256 | 17967 | 29913199 |
Pain | 38.12 | 16.66 | 40 | 21272 | 172601 | 29758565 |
Peripheral T-cell lymphoma unspecified | 37.06 | 16.66 | 14 | 21298 | 513 | 29930653 |
Hypogammaglobulinaemia | 36.24 | 16.66 | 30 | 21282 | 5222 | 29925944 |
Overdose | 35.95 | 16.66 | 8 | 21304 | 84329 | 29846837 |
Platelet count decreased | 35.82 | 16.66 | 160 | 21152 | 105969 | 29825197 |
Hypertension | 35.76 | 16.66 | 21 | 21291 | 121333 | 29809833 |
Leukopenia | 34.58 | 16.66 | 103 | 21209 | 56056 | 29875110 |
Aplasia pure red cell | 34.44 | 16.66 | 30 | 21282 | 5596 | 29925570 |
Somnolence | 34.25 | 16.66 | 13 | 21299 | 96750 | 29834416 |
Human polyomavirus infection | 34.21 | 16.66 | 14 | 21298 | 636 | 29930530 |
Enterococcal infection | 33.47 | 16.66 | 35 | 21277 | 8189 | 29922977 |
Cerebrovascular accident | 33.47 | 16.66 | 9 | 21303 | 83468 | 29847698 |
Cytomegalovirus syndrome | 33.01 | 16.66 | 9 | 21303 | 111 | 29931055 |
Pneumonia cytomegaloviral | 32.87 | 16.66 | 22 | 21290 | 2774 | 29928392 |
Procalcitonin increased | 32.82 | 16.66 | 16 | 21296 | 1102 | 29930064 |
Pain in extremity | 32.57 | 16.66 | 19 | 21293 | 110202 | 29820964 |
Metastases to muscle | 32.05 | 16.66 | 10 | 21302 | 203 | 29930963 |
Metastases to retroperitoneum | 31.82 | 16.66 | 10 | 21302 | 208 | 29930958 |
Haemolysis | 31.65 | 16.66 | 32 | 21280 | 7199 | 29923967 |
Rhabdomyolysis | 31.58 | 16.66 | 4 | 21308 | 63576 | 29867590 |
Paraneoplastic pemphigus | 31.43 | 16.66 | 8 | 21304 | 74 | 29931092 |
Fall | 31.06 | 16.66 | 51 | 21261 | 181821 | 29749345 |
Infusion site irritation | 30.90 | 16.66 | 9 | 21303 | 143 | 29931023 |
Cell-mediated cytotoxicity | 30.90 | 16.66 | 7 | 21305 | 37 | 29931129 |
Dermatitis exfoliative | 30.83 | 16.66 | 32 | 21280 | 7424 | 29923742 |
Insomnia | 30.68 | 16.66 | 14 | 21298 | 93322 | 29837844 |
Seizure | 30.51 | 16.66 | 16 | 21296 | 98459 | 29832707 |
Anaemia | 30.38 | 16.66 | 252 | 21060 | 207740 | 29723426 |
Pneumonitis | 30.35 | 16.66 | 63 | 21249 | 27391 | 29903775 |
Pneumocystis jirovecii infection | 30.03 | 16.66 | 16 | 21296 | 1329 | 29929837 |
Blood stem cell harvest failure | 29.71 | 16.66 | 6 | 21306 | 16 | 29931150 |
Dizziness | 29.41 | 16.66 | 59 | 21253 | 194850 | 29736316 |
Depression | 29.05 | 16.66 | 14 | 21298 | 90423 | 29840743 |
Anxiety | 28.74 | 16.66 | 14 | 21298 | 89857 | 29841309 |
Serum sickness | 28.33 | 16.66 | 17 | 21295 | 1773 | 29929393 |
Cytomegalovirus gastritis | 28.25 | 16.66 | 9 | 21303 | 196 | 29930970 |
Intentional product use issue | 27.51 | 16.66 | 72 | 21240 | 36368 | 29894798 |
Metastases to spleen | 27.38 | 16.66 | 10 | 21302 | 333 | 29930833 |
Metastases to bone marrow | 26.91 | 16.66 | 11 | 21301 | 498 | 29930668 |
Blood pressure decreased | 26.79 | 16.66 | 84 | 21228 | 46991 | 29884175 |
Haemolytic anaemia | 26.29 | 16.66 | 34 | 21278 | 9976 | 29921190 |
CD4 lymphocytes decreased | 26.06 | 16.66 | 17 | 21295 | 2053 | 29929113 |
Adenocarcinoma | 25.91 | 16.66 | 16 | 21296 | 1757 | 29929409 |
Blood bilirubin decreased | 25.85 | 16.66 | 9 | 21303 | 260 | 29930906 |
Stevens-Johnson syndrome | 25.19 | 16.66 | 45 | 21267 | 17511 | 29913655 |
Injection site phlebitis | 25.17 | 16.66 | 6 | 21306 | 41 | 29931125 |
Bacteraemia | 25.09 | 16.66 | 42 | 21270 | 15518 | 29915648 |
Blood lactate dehydrogenase increased | 24.82 | 16.66 | 49 | 21263 | 20552 | 29910614 |
Haematotoxicity | 24.65 | 16.66 | 26 | 21286 | 6144 | 29925022 |
Sphingomonas paucimobilis infection | 24.57 | 16.66 | 6 | 21306 | 46 | 29931120 |
Cardiac failure congestive | 24.30 | 16.66 | 15 | 21297 | 84392 | 29846774 |
Drug ineffective for unapproved indication | 24.07 | 16.66 | 34 | 21278 | 10846 | 29920320 |
Infusion site induration | 24.03 | 16.66 | 8 | 21304 | 201 | 29930965 |
Cytomegalovirus colitis | 23.92 | 16.66 | 17 | 21295 | 2362 | 29928804 |
Peripheral swelling | 23.71 | 16.66 | 7 | 21305 | 61067 | 29870099 |
Cytomegalovirus test positive | 23.46 | 16.66 | 20 | 21292 | 3625 | 29927541 |
Agitation | 23.30 | 16.66 | 5 | 21307 | 54068 | 29877098 |
Infusion site reaction | 23.13 | 16.66 | 11 | 21301 | 717 | 29930449 |
JC polyomavirus test positive | 22.19 | 16.66 | 10 | 21302 | 576 | 29930590 |
Fatigue | 22.00 | 16.66 | 136 | 21176 | 320537 | 29610629 |
Polyneuropathy | 21.91 | 16.66 | 34 | 21278 | 11789 | 29919377 |
Marginal zone lymphoma recurrent | 21.54 | 16.66 | 5 | 21307 | 30 | 29931136 |
Lymphoma | 21.47 | 16.66 | 31 | 21281 | 10090 | 29921076 |
Herpes zoster | 21.42 | 16.66 | 58 | 21254 | 29885 | 29901281 |
Hypoglycaemia | 21.39 | 16.66 | 5 | 21307 | 50976 | 29880190 |
Neuropathy peripheral | 21.35 | 16.66 | 103 | 21209 | 70372 | 29860794 |
Type IV hypersensitivity reaction | 21.07 | 16.66 | 12 | 21300 | 1136 | 29930030 |
Muscle spasms | 20.88 | 16.66 | 10 | 21302 | 64828 | 29866338 |
Myositis | 20.87 | 16.66 | 31 | 21281 | 10346 | 29920820 |
Oedema peripheral | 20.66 | 16.66 | 27 | 21285 | 105805 | 29825361 |
Metastases to meninges | 20.58 | 16.66 | 12 | 21300 | 1187 | 29929979 |
Hepatitis viral | 20.56 | 16.66 | 9 | 21303 | 484 | 29930682 |
Splenic marginal zone lymphoma | 20.18 | 16.66 | 5 | 21307 | 41 | 29931125 |
Tumour flare | 20.03 | 16.66 | 9 | 21303 | 515 | 29930651 |
Acquired C1 inhibitor deficiency | 19.99 | 16.66 | 4 | 21308 | 10 | 29931156 |
Mixed dementia | 19.92 | 16.66 | 7 | 21305 | 208 | 29930958 |
Bradycardia | 19.77 | 16.66 | 11 | 21301 | 65515 | 29865651 |
International normalised ratio increased | 19.41 | 16.66 | 5 | 21307 | 47734 | 29883432 |
Dermatitis exfoliative generalised | 19.26 | 16.66 | 16 | 21296 | 2799 | 29928367 |
Gastroenteritis sapovirus | 19.13 | 16.66 | 6 | 21306 | 124 | 29931042 |
Cytomegalovirus infection reactivation | 18.98 | 16.66 | 13 | 21299 | 1702 | 29929464 |
Mucosal inflammation | 18.82 | 16.66 | 56 | 21256 | 30438 | 29900728 |
Encephalitis cytomegalovirus | 18.80 | 16.66 | 8 | 21304 | 401 | 29930765 |
Cytomegalovirus enterocolitis | 18.77 | 16.66 | 10 | 21302 | 830 | 29930336 |
Gastrointestinal haemorrhage | 18.76 | 16.66 | 19 | 21293 | 83427 | 29847739 |
Hyperthermia | 18.66 | 16.66 | 29 | 21283 | 10070 | 29921096 |
Nocardiosis | 18.34 | 16.66 | 17 | 21295 | 3438 | 29927728 |
Nephrogenic diabetes insipidus | 18.03 | 16.66 | 11 | 21301 | 1182 | 29929984 |
Neoplasm recurrence | 17.98 | 16.66 | 13 | 21299 | 1854 | 29929312 |
Haemophagocytic lymphohistiocytosis | 17.93 | 16.66 | 28 | 21284 | 9763 | 29921403 |
Vision blurred | 17.74 | 16.66 | 4 | 21308 | 41812 | 29889354 |
Retinitis | 17.65 | 16.66 | 7 | 21305 | 293 | 29930873 |
H1N1 influenza | 17.48 | 16.66 | 10 | 21302 | 954 | 29930212 |
Hospitalisation | 17.34 | 16.66 | 5 | 21307 | 44314 | 29886852 |
Infusion site swelling | 17.30 | 16.66 | 12 | 21300 | 1604 | 29929562 |
Skin toxicity | 17.27 | 16.66 | 16 | 21296 | 3233 | 29927933 |
Encephalitis | 17.12 | 16.66 | 22 | 21290 | 6414 | 29924752 |
Nervous system disorder | 16.86 | 16.66 | 32 | 21280 | 13037 | 29918129 |
Aggression | 16.77 | 16.66 | 3 | 21309 | 36904 | 29894262 |
Cardio-respiratory arrest | 16.74 | 16.66 | 10 | 21302 | 57296 | 29873870 |
Cerebral aspergillosis | 16.72 | 16.66 | 11 | 21301 | 1347 | 29929819 |
Source | Code | Description |
---|---|---|
ATC | L01AA09 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS ALKYLATING AGENTS Nitrogen mustard analogues |
FDA MoA | N0000000236 | Alkylating Activity |
FDA EPC | N0000175558 | Alkylating Drug |
MeSH PA | D000477 | Alkylating Agents |
MeSH PA | D000970 | Antineoplastic Agents |
MeSH PA | D018906 | Antineoplastic Agents, Alkylating |
MeSH PA | D009676 | Noxae |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Chronic lymphoid leukemia, disease | indication | 92814006 | |
Follicular non-Hodgkin's lymphoma | indication | 308121000 | |
Indolent B-Cell Lymphoma | indication | ||
Mantle cell lymphoma | off-label use | 443487006 | |
Fluid volume disorder | contraindication | 1860003 | |
Hyperkalemia | contraindication | 14140009 | |
Acute nephropathy | contraindication | 58574008 | |
Hepatic failure | contraindication | 59927004 | |
Acute infectious disease | contraindication | 63171007 | |
Kidney disease | contraindication | 90708001 | DOID:557 |
Disease of liver | contraindication | 235856003 | DOID:409 |
Anemia | contraindication | 271737000 | DOID:2355 |
Pregnancy, function | contraindication | 289908002 | |
Thrombocytopenic disorder | contraindication | 302215000 | DOID:1588 |
Neutropenic disorder | contraindication | 303011007 | DOID:1227 |
Bone marrow depression | contraindication | 307762000 | |
Breastfeeding (mother) | contraindication | 413712001 | |
Smokes tobacco daily | contraindication | 449868002 | |
Chemotherapy-Induced Hyperuricemia | contraindication |
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 4.61 | acidic |
pKa2 | 6.18 | Basic |
pKa3 | 2.83 | Basic |
None
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
---|---|---|---|---|---|---|---|---|---|
100MG/4ML (25MG/ML) | BENDEKA | EAGLE PHARMS | N208194 | Dec. 7, 2015 | RX | SOLUTION | IV (INFUSION) | Dec. 7, 2022 | TREATMENT OF PATIENTS WITH CLL AND TREATMENT OF PATIENTS WITH INDOLENT B-CELL NHL THAT HAS PROGRESSED DURING OR WITHIN SIX MONTHS OF TREATMENT WITH RITUXIMAB OR A RITUXIMAB CONTAINING REGIMEN |
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Histone deacetylase 3 | Enzyme | IC50 | 7.60 | CHEMBL | |||||
Histone deacetylase 1 | Enzyme | IC50 | 7.77 | CHEMBL | |||||
Histone deacetylase 2 | Enzyme | IC50 | 8.05 | CHEMBL | |||||
Histone deacetylase 10 | Enzyme | IC50 | 7.14 | CHEMBL | |||||
Histone deacetylase 8 | Enzyme | IC50 | 6.97 | CHEMBL | |||||
Histone deacetylase 6 | Enzyme | IC50 | 8.22 | CHEMBL | |||||
DNA | DNA | OTHER | DRUG LABEL | DRUG LABEL |
ID | Source |
---|---|
9266D9P3PQ | UNII |
4027339 | VUID |
N0000179513 | NUI |
D07085 | KEGG_DRUG |
3543-75-7 | SECONDARY_CAS_RN |
4027339 | VANDF |
C0525079 | UMLSCUI |
CHEBI:135515 | CHEBI |
CHEMBL487253 | ChEMBL_ID |
CHEMBL1201734 | ChEMBL_ID |
DB06769 | DRUGBANK_ID |
D000069461 | MESH_DESCRIPTOR_UI |
5228 | INN_ID |
65628 | PUBCHEM_CID |
7478 | IUPHAR_LIGAND_ID |
1114693 | RXNORM |
132929 | MMSL |
241056 | MMSL |
25220 | MMSL |
275320 | MMSL |
d07121 | MMSL |
006925 | NDDF |
006926 | NDDF |
427812009 | SNOMEDCT_US |
428012008 | SNOMEDCT_US |
430082006 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
BELRAPZO | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42367-521 | INJECTION | 100 mg | INTRAVENOUS | NDA | 27 sections |
Bendeka | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63459-348 | INJECTION, SOLUTION | 25 mg | INTRAVENOUS | NDA | 31 sections |
TREANDA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63459-390 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 25 mg | INTRAVENOUS | NDA | 27 sections |
TREANDA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63459-391 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 100 mg | INTRAVENOUS | NDA | 27 sections |
TREANDA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63459-395 | INJECTION, SOLUTION, CONCENTRATE | 45 mg | INTRAVENOUS | NDA | 27 sections |
TREANDA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63459-396 | INJECTION, SOLUTION, CONCENTRATE | 180 mg | INTRAVENOUS | NDA | 27 sections |